Mary Jo Laffler
Mary Jo Laffler oversees US commercial content for Informa’s pharmaceutical news publications, working with a group of talented reporters and editors covering business, commercial and clinical news. She brings 16 years of experience reporting on the pharmaceutical industry for the Pink Sheet and affiliated publications, serving previously as Bureau Chief for Clinical Development and Business News, managing editor of the Pink Sheet and as one of the first managing editors for the Pink Sheet DAILY. While wearing many hats has given Mary Jo a wide-ranging knowledge of the commercial and regulatory challenges facing the pharmaceutical industry, her specialty is in analyzing drug development news and R&D strategy.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mary Jo Laffler
AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval
AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.
Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.
ASCO Review: Progress Is Where You Find It
In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine.
ASCO Review: Progress Is Where You Find It
In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting allowed other areas to shine.
Lartruvo Could Be A Failure Of The Drug, The Design Or The Disease
The presentation of the ANNOUNCE results, the failed confirmatory trial for Lilly’s Lartruvo, at ASCO re-opened questions about the accelerated approval and the appropriate way to study soft tissue sarcoma.
US Affordable Care Act Impact On Cancer Care Quantified At ASCO
A series of abstracts highlight the impact of the ACA and Medicaid expansion on ovarian cancer diagnosis, racial disparities in time to treatment and the impact of insurance type on myeloma survival.
Advertisement